Cargando…
A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer
Enzalutamide (ENZA), a second-generation androgen receptor antagonist, has significantly increased progression-free and overall survival of patients with metastatic prostate cancer (PCa). However, resistance remains a prominent obstacle in treatment. Utilizing a kinome-wide CRISPR-Cas9 knockout scre...
Autores principales: | Liu, Jinghui, Zhao, Yue, He, Daheng, Jones, Katelyn M., Tang, Shan, Allison, Derek B., Zhang, Yanquan, Chen, Jing, Zhang, Qiongsi, Wang, Xinyi, Li, Chaohao, Wang, Chi, Li, Lang, Liu, Xiaoqi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140619/ https://www.ncbi.nlm.nih.gov/pubmed/37075701 http://dx.doi.org/10.1016/j.xcrm.2023.101015 |
Ejemplares similares
-
Phosphorylation of AHR by PLK1 promotes metastasis of LUAD via DIO2-TH signaling
por: Li, Chaohao, et al.
Publicado: (2023) -
Generation of dual-gRNA library for combinatorial CRISPR screening of synthetic lethal gene pairs
por: Tang, Shan, et al.
Publicado: (2022) -
Epigenetics in prostate cancer treatment
por: Jones, Katelyn, et al.
Publicado: (2021) -
p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer
por: Liu, Jinghui, et al.
Publicado: (2020) -
Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
por: Vander Ark, Alexandra, et al.
Publicado: (2018)